CD44 Gene Polymorphisms in Breast Cancer Risk and Prognosis: A Study in North Indian Population

Background Cell surface biomarker CD44 plays an important role in breast cancer cell growth, differentiation, invasion, angiogenesis and tumour metastasis. Therefore, we aimed to investigate the role of CD44 gene polymorphisms in breast cancer risk and prognosis in North Indian population. Materials & Methods A total of 258 breast cancer patients and 241 healthy controls were included in the case-control study for risk prediction. According to RECIST, 114 patients who received neo-adjuvant chemotherapy were recruited for the evaluation of breast cancer prognosis. We examined the association of tagging SNP (rs353639) of Hapmap Gujrati Indians in Houston (GIH population) in CD44 gene along with a significant reported SNP (rs13347) in Chinese population by genotyping using Taqman allelic discrimination assays. Statistical analysis was done using SPSS software, version 17. In-silico analysis for prediction of functional effects was done using F-SNP and FAST-SNP. Results No significant association of both the genetic variants of the CD44 gene polymorphisms was found with breast cancer risk. On performing univariate analysis with clinicopathological characteristics and treatment response, we found significant association of genotype (CT+TT) of rs13347 polymorphism with earlier age of onset (P = 0.029, OR = 0.037). However, significance was lost in multivariate analysis. For rs353639 polymorphism, significant association was seen with clinical tumour size, both at the genotypic (AC+CC) (P = 0.039, OR = 3.02) as well as the allelic (C) (P = 0.042, OR = 2.87) levels. On performing multivariate analysis, increased significance of variant genotype (P = 0.017, OR = 4.29) and allele (P = 0.025, OR = 3.34) of rs353639 was found with clinical tumour size. In-silico analysis using F-SNP, showed altered transcriptional regulation for rs353639 polymorphism. Conclusions These findings suggest that CD44 rs353639 genetic variants may have significant effect in breast cancer prognosis. However, both the polymorphisms- rs13347 and rs353639 had no effect on breast cancer susceptibility.

[1]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[2]  Fang Liu,et al.  A Novel Gemini Vitamin D Analog Represses the Expression of a Stem Cell Marker CD44 in Breast Cancer , 2011, Molecular Pharmacology.

[3]  J. Murabito,et al.  Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study , 2007, BMC Medical Genetics.

[4]  Dino Amadori,et al.  The global breast cancer burden: variations in epidemiology and survival. , 2005, Clinical breast cancer.

[5]  B. Ponder,et al.  Prevalence and penetrance of mutations in BRCA1 and BRCA2 in a population based series of breast cancer cases , 2000 .

[6]  J. Bell,et al.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Laura H. Tang,et al.  Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma , 2011, International journal of cancer.

[8]  A. Levine,et al.  Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. , 2010, Cancer research.

[9]  M. Nagarkatti,et al.  T-cell-receptor-independent activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and gp90MEL-14. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Hagit Shatkay,et al.  F-SNP: computationally predicted functional SNPs for disease association studies , 2007, Nucleic Acids Res..

[11]  M. Götte,et al.  Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. , 2006, Cancer research.

[12]  L. Bourguignon,et al.  Hyaluronan-mediated CD44 Interaction with RhoGEF and Rho Kinase Promotes Grb2-associated Binder-1 Phosphorylation and Phosphatidylinositol 3-Kinase Signaling Leading to Cytokine (Macrophage-Colony Stimulating Factor) Production and Breast Tumor Progression* , 2003, Journal of Biological Chemistry.

[13]  CD44 rs13347 C>T polymorphism predicts breast cancer risk and prognosis in Chinese populations , 2012, Breast Cancer Research.

[14]  M. Nagarkatti,et al.  Implications of single nucleotide polymorphisms in CD44 exon 2 for risk of breast cancer , 2011, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[15]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Bankfalvi,et al.  Gains and losses of CD44 expression during breast carcinogenesis and tumour progression , 1998, Histopathology.

[17]  Chia-Hung Liu,et al.  FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization , 2006, Nucleic Acids Res..

[18]  T. Mak,et al.  CD44-Deficient Mice Exhibit Enhanced Hepatitis After Concanavalin A Injection: Evidence for Involvement of CD44 in Activation-Induced Cell Death1 , 2001, The Journal of Immunology.

[19]  L. Bourguignon.  CD44-Mediated Oncogenic Signaling and Cytoskeleton Activation During Mammary Tumor Progression , 2001, Journal of Mammary Gland Biology and Neoplasia.

[20]  M. Nagarkatti,et al.  Hyaluronate-CD44 interactions can induce murine B-cell activation. , 1997, Blood.

[21]  J. López,et al.  CD44 attenuates metastatic invasion during breast cancer progression. , 2005, Cancer research.

[22]  Michael F Clarke,et al.  The biology of cancer stem cells. , 2007, Annual review of cell and developmental biology.

[23]  L. Bourguignon,et al.  CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. , 1998, Frontiers in bioscience : a journal and virtual library.

[24]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[25]  P. Goodfellow,et al.  The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11 , 1982, European journal of immunology.

[26]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[27]  Wj Gauderman,et al.  QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies , 2006 .

[28]  P. Johnston,et al.  The emerging role of CD44 in regulating skeletal micrometastasis. , 2006, Cancer letters.

[29]  Anglian Breast Cancer Study Group.  Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases , 2000 .

[30]  Michael T. Fisher,et al.  Targeted Deletion of CD44v7 Exon Leads to Decreased Endothelial Cell Injury but Not Tumor Cell Killing Mediated by Interleukin-2-activated Cytolytic Lymphocytes* , 2003, Journal of Biological Chemistry.

[31]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[32]  S. Seal,et al.  Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.

[33]  Alexander M. Seifalian,et al.  Stem Cells and Cancer: An Overview , 2007, Stem Cell Reviews.

[34]  M. Washington,et al.  A Blood Group-related Polymorphism of CD44 Abolishes a Hyaluronan-binding Consensus Sequence without Preventing Hyaluronan Binding (*) , 1996, The Journal of Biological Chemistry.

[35]  Michael T. Fisher,et al.  Role of CD44 and Its v7 Isoform in Staphylococcal Enterotoxin B-Induced Toxic Shock: CD44 Deficiency on Hepatic Mononuclear Cells Leads to Reduced Activation-Induced Apoptosis That Results in Increased Liver Damage , 2005, Infection and Immunity.

[36]  M. Zöller,et al.  CD44 in Cancer Progression: Adhesion, Migration and Growth Regulation , 2003, Journal of Molecular Histology.

[37]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[38]  M. Nagarkatti,et al.  Unique SNP in CD44 intron 1 and its role in breast cancer development. , 2010, Anticancer research.